---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000095"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:47:48.075100+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Centessa reports Q1 net loss $50.7M, cash $346.2M; advancing SerpinPC, LB101 trials

## Summary
- Cash $346.2M as of Mar 31, expected to fund operations into 2026; no draw on Oberland credit facility.
- Net loss attributable to shareholders $50.7M vs $54.5M YoY; R&D $32.8M (down 11%), G&A $16.1M (up 12%).
- SerpinPC registration program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected H2 2023.
- LB101 (PD-L1xCD47 LockBody) Phase 1/2a first-in-human trial dosing subjects for solid tumors.
- ORX750 (OX2R agonist for narcolepsy) in IND-enabling activities; preclinical data planned at 2023 scientific meeting.

## SEC filing metadata
- accession: 0001847903-23-000095
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/0001847903-23-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/cnta-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000095
- JSON: https://secwatch.observer/filing/0001847903-23-000095.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000095.txt

## Key facts
- Earnings Releases
  Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2023 results: net income Net Loss Attributable to Ordinary Shareholders: $50.7 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: Net Loss Attributable to Ordinary Shareholders: $50.7 million
  - Result: reported results
  source text: Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/0001847903-23-000095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.